Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.
about
PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasionLoss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth.Cell matrix adhesions in cancer: The proteins that form the glue.Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor.
P2860
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Genome-wide functional genetic ...... riple-negative breast cancers.
@en
type
label
Genome-wide functional genetic ...... riple-negative breast cancers.
@en
prefLabel
Genome-wide functional genetic ...... riple-negative breast cancers.
@en
P2093
P2860
P356
P1433
P1476
Genome-wide functional genetic ...... riple-negative breast cancers.
@en
P2093
Ann D Thor
Christopher C Porter
Christy M Gearheart
Gregory D DeGala
Hamid H Gari
James R Lambert
Kathleen C Torkko
M Scott Lucia
Susan Fosmire
P2860
P304
15757-15771
P356
10.18632/ONCOTARGET.7462
P407
P577
2016-02-17T00:00:00Z